Table 1.
Patient characteristics.
| Clinical Characteristics | Stage III patients (n = 4) | Stage IV patients (n = 15) |
|---|---|---|
| Age – median (range) | 73 (64–84) | 65 (30-88) |
| Sex – no. (%) | ||
| Male | 2 (50) | 13 (87) |
| Female | 2 (50) | 2 (13) |
| AJCC tumor stage (89) – no. (%) | ||
| M1a or M1b | NA | 5 (33) |
| M1c | NA | 5 (33) |
| M1d | NA | 5 (33) |
| Mutation – no. (%) | ||
| BRAF V600 | 0 (0) | 8 (53) |
| BRAF non-V600 | 0 (0) | 1 (7) |
| NRAS | 2 (50) | 4 (27) |
| BRAF/NRAS WT | 2 (50) | 2 (13) |
| Timing of blood draw* | (n = 5) | (n = 16) |
| Pre (treatment naïve) or at time of treatment progression | 4 (80) | 13 (81) |
| EDT (within 3 weeks) | 1 (20) | 3 (19) |
*One patient from stage III cohort and 1 patient from stage IV cohort had 2 samples. EDT patients did not respond (no complete or partial responders) to treatment.
AJCC, American Joint Committee on Cancer; EDT, early during therapy; NA, not applicable.